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CASE REPORT
ABSTRACT
We describe a patient with a prolonged aPTT who was diagnosed
as having factor XI deficiency after a rather large hematoma was
formed after angiography. Factor XI deficiency affects 1 in 1 million
people, but it is more common in Ashkenazim with a gene frequency
of 5% to 11%, being 0.3% homozygotes. These individuals usually
do not present hemorrhagic events, except in cases of trauma or
surgery. These patients should be identified by routine coagulation
screening; bleeding could be prevented by use of fresh human
plasma or plasma concentrates.
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Resumo
O Fator XI da via interna da cascata de coagulação é fundamental
para a produção de tromboplastina endógena e a sua deficiência
leva a um quadro clínico hemorrágico, conhecido como hemofilia
C. Esta deficiência é objeto do presente caso, com particular ênfase
na alta freqüência gênica entre o grupo étnico de judeus Ashkenazi.
Descritores: Deficiência do fator XI; Transtornos de proteínas de
coagulação 
INTRODUCTION
No production of endogenous thromboplastin or
activation of clotting Factor X is required to convert
prothrombin into thrombin, which acts on fibrinogen
converting it into fibrin; later on, Factor XIII stabilizes
fibrin clot.
The most frequent hereditary diseases impairing
activation of Factor X comprise Factor VIII deficiency
– the classic Hemophilia A, followed by Factor IX
deficiency – Hemophilia B, Factor VII deficiency –
extrinsic pathway, and acquired inhibitors of these factors.
In laboratory tests, these deficiencies are
demonstrated by prolonged activated partial
thromboplastin time (aPTT), and this finding leads to
investigation of these factors or inhibitors.
CASE REPORT
I. F., male, 70-years-old, was admitted to hospital due
to onset of intense precordial pain two hours before.
He reported chest pain for the past three days, but not
as intense and frequent as at admission.
The pain had characteristics of coronary insufficiency;
the patient suffered from hypertension and dyslipidemia
and had been treated at home. He did not report other
diseases and had no history of hemorrhage.
The patient was submitted to hemodynamic study
revealing that the middle third of the right coronary artery
was 90% occluded, the anterior descending artery was
80% occluded, and parietal lesions in other coronary
arteries. He underwent angioplasty with stent placement
in the two sites mentioned above. Intraoperative
echocardiogram showed left ventricular hypertrophy and
mild mitral and aortic valvular insufficiency.
Blood tests did not show increased CK-MB and
troponin values, however aPTT was persistently prolonged,
leading to delayed withdrawal of the vascular catheter in
the right femoral artery. Investigation of prolonged aPTT
revealed the patient had Factor XI deficiency (table 1).
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DISCUSSION
Factor XI deficiency was described by Rosenthal et al.
in 1953(1), and was called hemophilia C. It has an
incomplete autosomal recessive pattern of inheritance.
The prevalence in the general population is 1 in 1
million, but it is frequent among Ashkenazi Jews, in
whom a gene frequency of 5% to 11% is estimated,
being over 0.3% homozygotes(2-5). This deficiency is
caused by three types of mutation: I) splicing mutations;
II) stop codon with a non-functional molecule; and
III) substitution of an amino acid and molecular
dysfunction(6). Mutation types II and III occur in the
ethnic group mentioned(7). The disease progresses with
few hemorrhagic events, such as gingival bleeding,
epistaxis, menorrhagia and hematuria. However, after
trauma or any invasive procedure, a significant bleeding
may occur, as observed in this case, when a hematoma
was formed in the femoral region.
Factor XI deficiency interferes in clotting cascade
since it is one of the factors involved in the intrinsic
pathway to activate factor X.
Treatment or prevention may be carried out using
fresh human plasma (initially 15 ml/kg, later 3-6 ml/kg
for 12-24 hours), or Factor XI concentrate or
recombinant Factor VII. In case of Factor XI inhibitor,
we recommend using FEIBA(8).
Table 1. Clotting study
Date Sept 17 Sept 18 Sept 18 Sept 20 Sept 20 Reference value
PT 16.6 15.9 15.6 15.1 15.6 seconds
Activity 72% 77% 80% 85% 80% (70-100) %
INR 1.25 1.19 1.16 1.12 1.16 (0.96-1.25)
APT 101.6 88.1 90.8 88.8 82.7 seconds
Normal patient ratio 3.28 2.84 2.93 2.86 2.67 (0.90-1.25)
Normal control 31.0 seconds
Level of Factor XI < 1% (50-150%) %
Level of Factor IX 92.0 (60.0-150.0) %
Level of Factor VIII 115.0 (60.0-150.0) %
CONCLUSION
The present case illustrates that even with no history
of bleeding, especially among Ashkenazi Jews, a
clotting study should be performed before any invasive
procedure. If a prolonged aPTT is found, it is imperative
to investigate Factor XI deficiency, in view of the high
frequency of this disease in this ethnic group.
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